NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
Status:
Recruiting
Trial end date:
2024-01-18
Target enrollment:
Participant gender:
Summary
The main purposes of the dose escalation part of this study is to determine the following in
participants with gastric or gastro-esophageal junction (GEJ) or esophageal adenocarcinoma
(EAC):
- Safety and tolerability of NT-I7 in combination with nivolumab
- Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D)
The main purposes of Phase 2 of this study is to make a preliminary assessment of the
antitumor activity and long-term survival of NT-I7 in combination with nivolumab in
participants with gastric or GEJ or EAC.